Lever R - Search Results

1

Comparative binding of disulfide-bridged PEG-Fabs.

Khalili H, Godwin A, Choi JW, Lever R, Brocchini S. Khalili H, et al. Among authors: lever r. Bioconjug Chem. 2012 Nov 21;23(11):2262-77. doi: 10.1021/bc300372r. Epub 2012 Oct 18. Bioconjug Chem. 2012. PMID: 22994419

2

Fab-PEG-Fab as a potential antibody mimetic.

Khalili H, Godwin A, Choi JW, Lever R, Khaw PT, Brocchini S. Khalili H, et al. Among authors: lever r. Bioconjug Chem. 2013 Nov 20;24(11):1870-82. doi: 10.1021/bc400246z. Epub 2013 Nov 4. Bioconjug Chem. 2013. PMID: 24073593

3

PEGylation and its impact on the design of new protein-based medicines.

Ginn C, Khalili H, Lever R, Brocchini S. Ginn C, et al. Among authors: lever r. Future Med Chem. 2014;6(16):1829-46. doi: 10.4155/fmc.14.125. Future Med Chem. 2014. PMID: 25407370 Review.

4

Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.

Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS. Rampersaud N, et al. Among authors: lever r. Neuropeptides. 2012 Oct;46(5):183-93. doi: 10.1016/j.npep.2012.07.004. Epub 2012 Aug 22. Neuropeptides. 2012. PMID: 22921965 Retracted.

5

Preparation and characterisation of hexamidine salts.

Parisi N, Matts PJ, Lever R, Hadgraft J, Lane ME. Parisi N, et al. Among authors: lever r. Int J Pharm. 2015 Sep 30;493(1-2):404-11. doi: 10.1016/j.ijpharm.2015.07.071. Epub 2015 Jul 30. Int J Pharm. 2015. PMID: 26235920

6

Topical delivery of hexamidine.

Parisi N, Paz-Alvarez M, Matts PJ, Lever R, Hadgraft J, Lane ME. Parisi N, et al. Among authors: lever r. Int J Pharm. 2016 Jun 15;506(1-2):332-9. doi: 10.1016/j.ijpharm.2016.04.069. Epub 2016 Apr 26. Int J Pharm. 2016. PMID: 27130367

7

Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.

Abuirmeileh A, Harkavyi A, Rampersaud N, Lever R, Tadross JA, Bloom SR, Whitton PS. Abuirmeileh A, et al. Among authors: lever r. J Pharm Pharmacol. 2012 May;64(5):637-43. doi: 10.1111/j.2042-7158.2011.01394.x. Epub 2012 Mar 27. J Pharm Pharmacol. 2012. PMID: 22471359

8

Hexamidine salts - applications in skin health and personal care products.

Parisi N, Matts PJ, Lever R, Hadgraft J, Lane ME. Parisi N, et al. Among authors: lever r. Int J Cosmet Sci. 2017 Aug;39(4):361-365. doi: 10.1111/ics.12392. Epub 2017 Mar 7. Int J Cosmet Sci. 2017. PMID: 28129440 Review.

9

Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton P. Rampersaud N, et al. Among authors: lever r. Br J Pharmacol. 2012 Dec;167(7):1467-79. doi: 10.1111/j.1476-5381.2012.02100.x. Br J Pharmacol. 2012. PMID: 22774922 Free PMC article. Retracted.

10

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.

Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Harkavyi A, et al. Among authors: lever r. J Neuroinflammation. 2008 May 21;5:19. doi: 10.1186/1742-2094-5-19. J Neuroinflammation. 2008. PMID: 18492290 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

115 results

Search Page